GlobeImmune Files For IPO

Louisville, Colorado-based GlobeImmune, the developer of biopharmaceuticals aimed at treating cancer and infectious diseases, filed for an IPO Tuesday, saying it is looking to raise up to $69M on the NASDAQ Global Market. The firm is looking to trade as GBIM. The firm's IPO is being underwritten by Wells Fargo Securities, Piper Jaffray, and JMP Securities. The company is led by Timothy Rodell, and is backed by Celgene, HealthCare Ventures, Morgenthaler Partners, Wexford-Kappa Investors, Sequel Ventures, Lilly Ventures, and Medica Venture Partners, among others.